Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: A review

International Clinical Psychopharmacology

Volumn 15, Issue SUPPL. 2, 2000, Pages

  Murphy, T K ^a   Bengtson, M A ^a   Tan, J Y ^a   Carbonell, E ^a   Levin, G M ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Anxiety disorders; Child; Citalopram; Flupxetine; Fluvoxamine; Paroxetine; Sertraline; SSRIs; Treatment

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADOLESCENT; ANXIETY NEUROSIS; ARTICLE; CHILD; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; HUMAN; MENTAL DISEASE; MUTISM; OBSESSION; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; SEPARATION ANXIETY; SOCIAL PHOBIA;

EID: 0033736346     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200008002-00008     Document Type: Article

References (135)

1. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population
2. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression, pharmacokinetics, tolerability, and efficacy
3. Summary of the practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder
4. AACAP practice parameters for the assessment and treatment of children and adolescents with post-traumatic stress disorder
5. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression
6. Fluoxetine-induced memory impairment in an adolescent
7. Movement disorder with fluoxetine
8. Fluoxetine treatment of children and adolescents with obsessive-compulsive disorders: An open-label trial
9. Psychopathology of childhood social phobia
10. Geographical/interracial differences in polymorphic drug oxidation - Current state of knowledge of cytochromes P450 2D6 and 2C19
11. Panic disorder and agoraphobia in consecutively referred children and adolescents
12. Fluoxetine for childhood anxiety disorders
13. Pharmacologic treatment for children and adolescents with anxiety disorders
14. Panic disorder in children and adolescents
15. Elective mutism as a variant of social phobia
16. Treatment of elective mutism with fluoxetine: Double-blind, placebo controlled study
17. Psychiatric characteristics of children with selective mutism, a pilot study
18. Paroxetine treatment of trichotillomania in an adolescent
19. The selective mutism controversy
20. Fluoxetine and memory impairment
21. Seizure after isolated fluoxetine overdose
22. Pediatric sertraline overdose
23. A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania
24. Clinical implications of anti-depressant pharmacokinetics and pharmacogenetics
25. Clinical profile, comorbidity, and treatment history in 123 hair pullers, a survey study
26. An open-label trial of fluoxetine for obsessive-compulsive disorder in Gilles de la Tourette's syndrome
27. Generalized anxiety disorder: Neurobiological and pharmacotherapeutic perspectives
28. Fluoxetine treatment of children and adults with autistic disorder and mental retardation
29. Management of posttraumatic stress disorder, diagnostic and therapeutic issues
30. Behavior therapy versus clomipramine for the treatment of obsessive-compulsive disorder in children and adolescents
31. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder - A multicenter trial
32. The use of fluoxetine in an adolescent with Prader-Willi syndrome
33. Effects of fluoxetine treatment in young children with idiopathic autism
34. Pharmacogenetics and drug metabolism of newer antidepressant agents
35. Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology, a review of published experience
36. SSRI-induced mania in obsessive-compulsive disorder
37. Practical guidelines for the assessment and treatment of selective mutism
38. Fluoxetine treatment of children with selective mutism, an open trial
39. Systematic assessment of 50 children with selective mutism
40. The use of fluoxetine in Gilles de la Tourette syndrome and obsessive compulsive behaviors, preliminary clinical experience
41. Fluoxetine and tics in an adolescent
42. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression
43. Nontricyclic antidepressants: Current trends in children and adolescents
44. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children
45. Open fluoxetine treatment of mixed anxiety disorders in children and adolescents
46. Fluoxetine in treatment of adolescent patients with autism, a longitudinal open trial
47. Emergence of symptoms of Tourette's syndrome during fluvoxamine treatment of obsessive-compulsive disorder
48. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents
49. Paroxetine pharmacokinetics in depressed children and adolescents
50. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder
51. A controlled trial of clomipramine in childhood obsessive compulsive disorder
52. Obsessive compulsive disorder in adolescence: An epidemiological study
53. Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder
54. Mania induced by sertraline in a pre-pubertal child
55. Serotonin syndrome in a child after a single dose of fluvoxamine
56. Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder
57. Pharmacogenetic phenotyping and genotyping, present status and future potential
58. Biological approaches to treatment-resistant obsessive compulsive disorder
59. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder
60. Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents
61. SSRI-induced mania
62. Sertraline-induced behavioral activation during the treatment of an adolescent with major depression
63. Trichotillomania, clomipramine, topical steroids
64. Brief report, trichotillomania in an autistic male
65. A risk-benefit assessment of pharmacotherapy for anxiety disorders in children and adolescents
66. SSRI-induced mania
67. Comprehensive management of trichotillomania in a young autistic girl
68. Paroxetine-pimozide drug interaction
69. Serotonergic drugs in trichotillomania, treatment results in 12 patients
70. Fluoxetine in children and adolescents with mood disorders, a chart review of efficacy and adverse effects
71. Psychoactive medication prescribing practices for U.S. children: Gaps between research and clinical practice
72. SSRI and EPS with fluoxetine
73. Sertraline intoxication in a child
74. More on SSRI-induced mania
75. Self-reports of panic attacks and manifest anxiety in adolescents
76. Child panic revisited
77. Analysis of sertraline-only overdoses
78. Trichotillomania, a review
79. A study of the effectiveness of a specific treatment for elective mutism
80. A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette's syndrome
81. The new anti-depressants. Selective serotonin reuptake inhibitors
82. Fluvoxamine in selective mutism
83. Panic disorder in children and adolescents
84. Potential withdrawal syndrome associated with SSRI withdrawal
85. The role of serotonin re-uptake inhibitors in preventing recurrent unexplained childhood syncope - A preliminary report
86. A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents
87. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison
88. Citalopram in the treatment of early-onset panic disorder and school phobia
89. Fluoxetine for adolescents with obsessive-compulsive disorder
90. Carbamazepine for PTSD
91. Cognitive-behavioral psychotherapy for children and adolescents with OCD, a review and recommendations for treatment
92. Sertraline in children and adolescents with obsessive-compulsive disorder, a multicenter randomized controlled trial
93. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics
94. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder
95. Update, clinically significant cytochrome P450 drug interactions
96. Panic disorder in children and adolescents: A review
97. Fluoxetine for (s)elective mutism
98. A review of developmental aspects of cytochrome P450
99. Paroxetine-induced mania
100. Posttraumatic stress disorder in children; a review of the past 10 years
101. The role of serotonin in autism-spectrum disorders
102. Clinical controlled trial of clomipramine in adolescents with obsessive compulsive disorder
103. Use of selective serotonin reuptake inhibitors for the treatment of childhood panic disorder: A pilot study
104. Fluoxetine overdose in an adolescent
105. Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders, preliminary clinical experience
106. Behavioral side effects of fluoxetine in children and adolescents
107. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive compulsive disorder
108. A controlled trial of fluvoxamine for obsessive-compulsive disorder in children and adolescents
109. Effects of SSRIs on sexual function, a critical review
110. Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder
111. A pilot study of clomipramine in young autistic children
112. Fluoxetine has no marked effect on tic symptoms in patients with Tourette's syndrome, a double-blind placebo-controlled study
113. Current concepts in the treatment of panic disorder
114. Fluoxetine treatment of trichotillomania and depression in a prepubertal child
115. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination
116. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder
117. A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania
118. Obsessive-compulsive disorder in children and adolescents. Clinical phenomenology of 70 consecutive cases
119. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania
120. Citalopram in the treatment of depression and other potential uses in psychiatry
121. Child and adolescent obsessive-compulsive disorder treated with citalopram, findings from an open trial of 23 cases
122. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder
123. Child and adolescent psychopharmacology: Important developmental issues
124. Frequency of obsessive-compulsive disorder in a community sample of young adolescents
125. Mania associated with fluoxetine treatment in adolescents
126. Developmental perspectives in pediatric psychopharmacology
127. Diagnosis of panic disorder in prepubertal children
128. Effect of SSRI antidepressants on ejaculation: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine and sertraline
129. Fluvoxamine in childhood OCD: Long-term treatment
130. Eating disorders, progress and problems
131. Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life
132. Absence of cardiovascular adverse effects of sertraline in children and adolescents
133. The relationship of agoraphobia and panic in a community sample of adolescents and young adults
134. Fluoxetine in the multi-modal treatment of a pre-school child with selective mutism